CHIKV VLP vaccine booster + Placebo booster
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chikungunya Virus Infection
Conditions
Chikungunya Virus Infection
Trial Timeline
Aug 30, 2023 → Aug 1, 2028
NCT ID
NCT06007183About CHIKV VLP vaccine booster + Placebo booster
CHIKV VLP vaccine booster + Placebo booster is a phase 3 stage product being developed by Bavarian Nordic for Chikungunya Virus Infection. The current trial status is active. This product is registered under clinical trial identifier NCT06007183. Target conditions include Chikungunya Virus Infection.
What happened to similar drugs?
0 of 10 similar drugs in Chikungunya Virus Infection were approved
Approved (0) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06007183 | Phase 3 | Active |
Competing Products
20 competing products in Chikungunya Virus Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VAL-181388 | Moderna | Phase 1 | 0 |
| mRNA-1944 | Moderna | Phase 1 | 0 |
| CHIKV VLP/unadjuvanted + CHIKV VLP/adjuvanted + Placebo | Bavarian Nordic | Phase 2 | 32 |
| Chikungunya | Bavarian Nordic | Phase 2 | 32 |
| CHIKV VLP/adjuvant + Placebo | Bavarian Nordic | Phase 3 | 37 |
| CHIKV VLP, adjuvanted | Bavarian Nordic | Phase 2 | 32 |
| CHIKV VLP/adjuvant + Placebo | Bavarian Nordic | Phase 3 | 37 |
| CHIKV VLP vaccine + Placebo | Bavarian Nordic | Phase 3 | 44 |
| CHIKV VLP vaccine + Placebo | Bavarian Nordic | Phase 3 | 44 |
| Live-attenuated CHIKV vaccine VLA1553 | Valneva SE | Pre-clinical | 27 |
| VLA1553 | Valneva SE | Phase 3 | 26 |
| Live-attenuated CHIKV vaccine VLA1553 | Valneva SE | Pre-clinical | 24 |
| Biological Vaccine VLA1553 | Valneva SE | Phase 3 | 34 |
| VLA1553 full dose + VLA1553 half dose + Control | Valneva SE | Phase 2 | 29 |
| Active + Placebo | Valneva SE | Phase 3 | 34 |
| Live-attenuated CHIKV vaccine VLA1553 + Vaccine(s) approved for use during pregnancy by the MoH | Valneva SE | Pre-clinical | 27 |
| VLA1553 | Valneva SE | Phase 3 | 38 |
| VLA1553 + Control | Valneva SE | Phase 3 | 26 |
| VLA1553 + Placebo | Valneva SE | Phase 3 | 34 |
| VLA1553 | Valneva SE | Phase 1 | 23 |